Loading clinical trials...
Loading clinical trials...
A Prospective, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Oral Paricalcitol in Retarding Cardiac Hypertrophy, Reducing Inflammation and Atherosclerosis in Stage 3 - 5 Chronic Kidney Disease
Conditions
Interventions
paricalcitol
Locations
2
Hong Kong
Queen Mary Hospital
Hong Kong, Hong Kong
University of Hong Kong, Queen Mary Hospital
Hong Kong, Hong Kong
Start Date
October 1, 2008
Primary Completion Date
June 1, 2011
Completion Date
June 1, 2011
Last Updated
January 10, 2017
NCT07241390
NCT06926660
NCT06717698
NCT07450820
NCT06306963
NCT04592640
Lead Sponsor
The University of Hong Kong
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions